PT-141

PT-141, or bremelanotide, is a melanocortin receptor agonist used primarily for libido enhancement and the treatment of sexual dysfunction. Users typically administer 1 mg to 2 mg subcutaneously, though community reports show a wide dosing range starting as low as 200 µg. While the peptide is FDA-approved for Hypoactive Sexual Desire Disorder, the broader evidence base for other indications remains thin and largely exploratory. Users occasionally report nausea, GI distress, and flushing, though these side effects are not consistently documented across the community. Prospective users should note that the off-label evidence base is significantly more limited than common discourse suggests.

Half-life~2 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.93.42.33.52.94.0

Research Evidence

Evidence shape

PT-141 carries high-tier clinical evidence, supported by 19 published human studies primarily focused on the treatment of sexual dysfunction. While the strongest trials demonstrate efficacy in Hypoactive Sexual Desire Disorder and Female Sexual Arousal Disorder through four blinded, sponsor-backed studies, the broader research landscape remains thin. Of the nine mapped indications, only two have published results, while the remaining seven consist of single-trial long-tail studies or exploratory research. This concentration of data in specific sexual health applications highlights a significant gap between the primary clinical focus and the peptide's wider, less-validated experimental use.

Depthhow much
10 registered trials
9 completed · 4 with posted results · 1 recruiting / active · combined n=2089
Breadthhow many areas
9 indications mapped
2 with results · 6 thin / exploratory · 1 animal-only · 5 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
4 blinded with results · 5 distinct sponsors · AE rows aggregated from 3 trials · 10 linked publications on registered trials
Breadth and depth30 rows captured
Human
direct clinical signal
29
Animal
translational support
1
In vitro
mechanistic support
0
HighMediumLow

Anecdotal efficacy

PT-141 side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Better Peptide
--
100 mg
$29.99
$0.3/mg
2
Sentinel Valor
US
10 mg
$5.99
$0.6/mg
3
Mrbeetoe
--
100 mg
$62.00
$0.62/mg
4
peptidesourcehub.com
--
100 mg
$109.90
$1.1/mg
5
Nurev Peptides
--
10 mg
$13.99
$1.4/mg
6
Wholesale Peptides
GB
100 mg×10
$147.65
$1.48/mg

price offers can be sorted by column

1-6 of 283

PT-141 dosing & protocol

How PT-141 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 28
Typical dose
1.8 mg1.8 mg – 8 mg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 16 reported doses · darker = more
Frequency
twice daily
Route
subQ

Research trials administered PT‑141 subcutaneously twice daily, most often at a fixed 1.75 mg dose, with a reported range from 1.8 mg up to 8 mg per administration.

28 sources
Clinician practice
Doctor & published-protocol guidance · n = 5
Typical dose
1.8 mg1 mg – 2 mg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 7 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

Across five clinician sources, the dose sits at 1–2 mg subcutaneously, with 1.75 mg appearing most often; three sources specify daily dosing, the prescribing monograph specifies as-needed administration at 1.75 mg, and no cycling protocol was captured.

5 sources
Anecdotal
Community-reported real-world use · n = 59
Typical dose
1 mg200 µg – 2.5 mg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 69 reported doses · darker = more
Frequency
unspecified
Route
subQ

The typical dose is 1 mg, with a reported range of 200 µg to 2.5 mg; no consistent frequency or cycling pattern was reported in the community data.

59 sources

Regulatory safety notes

Warnings and precautions
  • • Transient increase in blood pressure and decrease in heart rate: Occurs after each dose and usually resolves within 12 hours. Consider the patient's cardiovascular risk before initiating VYLEESI and periodically during treatment and ensure blood pressure is w…
  • • Focal hyperpigmentation: Reported by 1% of patients who received up to 8 doses per month, including involvement of the face, gingiva and breasts. Higher risk in patients with darker skin and with daily dosing. Resolution was not confirmed in some patients. Co…
  • • Nausea: Reported by 40% of patients who received up to 8 monthly doses, requiring anti-emetic therapy in 13% of patients and leading to premature discontinuation for 8% of patients. Improved for most patients with the second dose. Consider discontinuing VYLEE…
Contraindications
  • • VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease [see Warnings and Precautions (5.1) ]. Uncontrolled hypertension or known cardiovascular disease.
Drug interactions
  • • VYLEESI may slow gastric emptying and impact absorption of concomitantly administered oral medications. (7.1) VYLEESI may significantly decrease the systemic exposure of orally-administered naltrexone; avoid use with orally administered naltrexone-containing…

Related peptides

Kisspeptin-10HCGTriptorelinOxytocinGonadorelin